Interview with Joong Keun Cha, President & CEO, Yuhan
Yuhan is one of the largest and fastest growing pharmaceutical companies in South Korea, with a long history in the sector. In your view, what are the main elements that…
Address: 49-6, Daebang-dong, Dongjak-gu, Seoul,Republic of Korea
Tel: +82 2 828 0101
Upholding the founding spirit of Dr. Illhan, New ‘we shall provide the best pharmaceutical products for the nation and for the people’. Yuhan Pharmaceuticals is strongly committed to promote health through the development of excellence of pharmaceuticals preparing to become the global leader of pharmaceutical industry for the 21st century.
The Yuhan Research Institute realizes the vision for Yuhan in the future and is pressing ahead with development of market oriented of new pharmaceutical products, new drugs targeting the global market and pharmaceutical ingredients for global customers. Yuhan Research institute is doing its best to provide a platform on which Yuhan Corporation can reinvent itself as a leader of global pharmaceutical industry to upgrade the quality of human kind.
Yuhan is one of the largest and fastest growing pharmaceutical companies in South Korea, with a long history in the sector. In your view, what are the main elements that…
A wave of blockbuster biologics is set to lose patent protection, creating a major inflection point for the biosimilars market in 2025 and beyond. While Europe remains the global leader…
A roundup of the biggest pharma stories coming out of APAC, including Eisai’s deal with biotech SEED Therapeutics and share drop after Alzheimer’s rejection in the EU; Mayne Pharma’s lawsuit…
A roundup of some of the biggest stories from South Korean healthcare and pharma, including the government’s continuing standoff with doctors over medical reform plans; Merck’s plans for a new…
Despite its ageing population and growing need for healthcare, South Korea had just 2.6 doctors per 1,000 inhabitants in 2022, one of the lowest numbers among developed nations. To deal…
The latest pharma and healthcare news from APAC, including Celltrion’s plans to sell its Takeda portfolio to CBC; reforms to the South Korean national insurance system that may lead to…
Global medtech giant Medtronic is hoping that its latest acquisition – EOFlow, a South Korean wearable insulin patch maker – will enhance its competitiveness in the global diabetes market. …
A roundup of some of the most important recent stories from the burgeoning South Korean pharma and biotech industry, including a government plan to expand collaboration with the global innovation…
As big pharma continues to sharpen its focus on R&D by outsourcing other elements of the supply chain, including manufacturing, CDMOs have thrived. Samsung Biologics, one of the world’s top…
After launching the first Korean COVID-19 vaccine, SKYCovione, SK Bioscience is preparing for its next big milestone, a US subsidiary, with the appointment of two new executives who are already…
SK Bioscience’s announcement that the first batch of its domestically developed COVID vaccine has been shipped may mark a significant milestone in South Korea’s journey towards greater vaccine self-sufficiency. …
ExoCoBio’s CEO, Byong Seung Cho, went from biotech venture capital to setting up ExoCoBio, a company whose core technology is based on adipose stem-cell derived exosomes for regenerative medicine and…
South Korea has carved a place for itself as a dominant player in the global pharma and med-tech manufacturing industry with national companies Samsung Biologics and Celltrion leading the way.…
See our Cookie Privacy Policy Here
